[Proneuron1] ProCord Trial for Complete Spinal Cord Injury Now Live at Shepherd Center in Atlanta

[proneuron1 at list.proneuron.com]

PROCORD TRIAL FOR COMPLETE SPINAL CORD INJURY NOW LIVE AT SHEPHERD
CENTER IN ATLANTA

Atlanta, Georgia, May 25, 2005 ---- Shepherd Center announced today that
it is now a treatment site for Proneuron's Phase II, multi-center,
randomized-controlled trial of ProCord for complete spinal cord injury.
Shepherd Center has been enrolling patients in the study as an IRB
patient referral and follow up site for more than a year.  With the
completion of the establishment and operation of a specially designed
cell processing center at Cell Design LLC in Atlanta, Shepherd Center
has the necessary tools to implement the surgical segment of the
experimental therapy.

"The ProCord trial continues and is currently live at Shepherd Center.
We are now fully equipped to provide both the surgical and the
post-operative rehabilitation portions of this experimental treatment.
We look forward to continuing our participation in this very important
research," said David Apple, Jr., MD, Emeritus Medical Director of
Shepherd Center.

The Marcus Foundation provided the $3.2 million in financing used to
build the ProCord processing cell center at Cell Design and to begin the
implementation of the study at Shepherd Center.

"We are proud to be an active part of this worthy initiative and are
hopeful that this enormous effort will result in the improvement of the
well being of patients," said Dr. Robert McNally, President of Cell
Design LLC.

Dr. David Snyder, V.P. of Clinical Development at Proneuron commented,
"Timing is a crucial element in this study, from the admission of
patients through the implantation of the autologous cellular product.
It is important to remember that qualifying patients must be enrolled
within 12 days of their injury in order to receive ProCord within the
14-day study protocol window."

Patient, Immediate Family of Patient and/or Physician inquiries:
24 hour a day Patient Recruitment Center:
Email: clinical.trial at proneuron.com 
Telephone: 1-866-539-0767 (U.S. toll free) or 1-506-652-3486. 
Fax: 1-866-214-7078
*Callers outside of the U.S., please use standard international dialing
code
For complete details about the study: www.spinalcordtrial.com 

Shepherd Center in Atlanta is the country's largest catastrophic care
hospital specializing in the treatment of people with spinal cord injury
and disease, acquired brain injury, multiple sclerosis and other
neuromuscular disorders and urological problems.  Shepherd Center is the
largest Model Center for spinal cord injury in the country, serves as
one of the largest brain injury programs in Georgia, and is an official
Multiple Sclerosis Center, designated the National Multiple Sclerosis
Society-Georgia Chapter.  Founded in 1975, the 100-bed not-for-profit
hospital offers a continuum of health care services, from intensive care
through inpatient medical surgical care, rehabilitation, day program,
and outpatient and residential services. For more information, visit
www.shepherd.org.
For additional information, please contact Larry Bowie, Public
Relations, Shepherd Center, at 404-350-7708 or email
larry_bowie at shepherd.org

Proneuron Biotechnologies Inc. is a privately held biopharmaceutical
company developing products for the medical treatment of spinal cord
injuries and other disorders of the central nervous system. Its products
are based on proprietary technology licensed from Yeda for modulating
the interaction between the nervous and immune systems. The company's
products are currently being evaluated in several clinical studies
located in the U.S., Belgium and Israel. These include: an independently
managed, international, multi-center, randomized-controlled Phase II
trial of ProCord, autologous incubated macrophages, an experimental
procedure for spinal cord injuries and a Phase II program of Cop-1 for
the treatment of Huntington's disease (HD), Glaucoma and other
neurodegenerative diseases. The latter is being managed by Teva as part
of the Proneuron's strategic collaboration for development and
commercialization of Cop-1 for various neurodegenerative indications.
The Company is also developing PN277 for the treatment of additional
neurodegenerative diseases.
For additional information, please contact Marjie Hadad, Media Liaison,
Proneuron, Marjie.hadad at proneuron.com or at +972-54-536-5220.

Cell Design LLC, a wholly owned subsidiary of Cell Dynamics LLC, is a
privately held human tissue facility located in Smyrna Georgia. ProCord,
an autologous cell therapy for patients with spinal cord injuries, will
be processed in a cGMP laboratory in accordance with FDA guidelines.
Cell Dynamics LLC specializes in human tissues and is currently focusing
on the development of neonatal stem cells for therapeutic applications. 
For additional information, please contact Karen Baker, Professional
Relations Manager, Cell Dynamics LLC at 770 850-1270 extension 246 or
kbaker at celldynamicsllc.com.